title: Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.
abstract: The objective was to investigate the expression and prognostic value of CD59 expression in patients with diffuse large B-cell lymphoma (DLBCL) who underwent rituximab-cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP). The immunohistochemical expressions of CD59 in 186 well-characterized DLBCL patients were evaluated using tissue microarrays and then were related to known tumor- and patient-related variables and to survival. The results show that CD59 expressions were not statistically different between the germinal center B-cell-like-type and the activated B-cell-like-type. We also analyzed the relationships of CD59 expression with overall survival (OS) and progression-free survival (PFS) in DLBCL patients who were uniformly treated with R-CHOP. The high expression of CD59 was correlated with poor OS and PFS compared with the low-expression CD59. Our findings indicate that the CD59 level at onset is an independent predictor of the prognosis of DLBCL patients treated with R-CHOP.
authors.affiliation: Medical School of Southeast University, Nanjing, 210009, Jiangsu Province, China.
authors.forename: Guoqi
authors.initials: G
authors.lastname: Song
authors.forename: William C
authors.initials: WC
authors.lastname: Cho
authors.forename: Ling
authors.initials: L
authors.lastname: Gu
authors.forename: Bangshun
authors.initials: B
authors.lastname: He
authors.forename: Yuqin
authors.initials: Y
authors.lastname: Pan
authors.forename: Shukui
authors.initials: S
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018957:CD59 Antigens / Q000097:blood*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D000069283:Rituximab; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018957:CD59 Antigens; C051590:CD59 protein, human; D000069283:Rituximab; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone